A controlled study of 2 doses of idebenone in the treatment of alzheimer’s disease

Neuropsychobiology

Volumn 36, Issue 2, 1997, Pages 73-82

  Weyer, G ^a   Babej Dolle R M ^b   Hadler, Dietrich ^c   Hofmann, S ^c   Herrmann, W M ^d  

^a GOETHE UNIVERSITY   (Germany)

^b Takeda Europe Research and Development Centre GmbH ^*  (Germany)

^c Takeda Europe   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Alzheimer s disease; Clinical drug trials; Idebenone; Severity of the disease

Indexed keywords

IDEBENONE; NOOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TIME; TREATMENT OUTCOME; VERTIGO;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BENZOQUINONES; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030758077     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119366     Document Type: Article

References (26)

1. Nagaoka A, Nagai Y, Yamazaki N, Miyamoto M, Kiyota Y: Beneficial effects of idebcnone on memory impairment in rats, Drug Dev Res 1988;14:373-384.
2. Otomo E, Nanja E, Saso S, Narikawa H, Terao T, Yoshino Y, Sakuma T, Tsuchiya M, Nozaka M, Haynshi M, Asada T, Meguro M: Clinical evaluation of idebcnone in patients with cerebrovascular disease, Ther Res 1985:2:703-715.
3. Takeuchi S, Miyoshi K: A long-term trial of idebcnone in cerebrovascular diseases, Acta Gerontol 1986;36:58-68.
4. Dona G, Bonta L, Sacchelli C, Casale G, De Nicola P: A double blind study of the efficacy of idcbenone in the treatment of patients with cognitive deficit due to cerebrovascular disease, Acta Gerontol (Pavia) 1988:38:188-192.
5. Dona G, Bonta L, Sacchelli C, Casale G, De Nicola P: A double blind study to compare two dose regimens of idebcnone in the treatment of patients with cognitive deficit due to cerebrovascular disease, Acta Gerontol (Pavia) 1990: 40:54-62.
6. Bergamaseo B, Villardita C, Coppi R: Idcbenone in the treatment of multi-infarct dementia: A randomized, double-blind, placebo controlled multicentre trial, Arch Gerontol Geriatr 1992;15:271-278.
7. Marigliano V, Abate G, Barbagallo-Sangiorgi G, Bartorelli L, Capurso A, Cucinotta D, Cuz-zupoli M, Senin U, Tammaro A, Fioravanti M: Randomized, double-blind, placebo controlled multicenter study of idebcnone in patients suffering from multi-infarct dementia, Arch Gerontol Geriatr 1992;15:239-248.
8. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Dcnario M, Marigliano V, Tammaro A, Fioravanti M: Idebenone in senile dementia of Alzheimer type: A multicentrc study, Arch Gerontol Geriatr 1992;15:249-260.
9. Folstein ME, Folstcin SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 1975:12:189-198.
10. American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, ed 3-Revised, Washington, APA, 1987.
11. McKhann G, Drachman D, Folstein M, Katz-man R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the aus-picesof Department Health &Human Services Task Force on Alzheimer’s disease, Neurology 1984:34:939-944.
12. Hachinski VC, Illiff LD, Zihlka E, DuBoulay GH, McAllister VL, Marshall R, Ross-Russell RW, Symon L: Cerebral blood flow in dementia, Arch Neurol 1975:32:632-637.
13. Hamilton M: A rating scale for depression, J Neurol Ncurosurg Psychiatry 1960:23:56-62.
14. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease, Am J Psychiatry 1984;141:1356-1364.
15. Weyer G, Ihi R, Mohs RC, Schambach M, Dcnkcl A, Kaiser-Kehl H: Validierungsuntcr-suchungcn zu einer deutschen Version der Alzheimer’s Disease Assessment Scale ADAS, Z Geronlopsycholgcrontopsychiatric 1993:6:67-81.
16. National Institute of Mental Health: Clinical Global Impressions: in Guy W (ed): EDCEU Assessment Manual for Psychopharmacology, Rockville, NIMH, 1976. pp 217-222.
17. Oswald WD, Fleischmann UM: Das Niirn-bcrger-Altcrs-lnvcntar (NAI), Niimberg, Uni-versitat Erlangen, 1986.
18. Greene JG, et al: Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: A factor analytic study, Age Aging 1982:11:121-126.
19. CPMP Working Party on Efficacy of Medicinal Products: Antidcmentia Medicinal Products, Note for Guidance (Draft 5), Brussels, Commission of the European Communities, 1992.
20. Kanowski S, Ladurner G, Maurer K, Oswald WD, Stein U: Empfchlungen zur Evaluierung der Wirksamkcit von Nootropika, Z Geronto-psycholgerontopsychiatriv 1990:3:67-79.
21. Kern U, Mengcs K: Proof of efficacy of nootro-pics for the indication’dementia' (phase III)-recommendations, Pharmacopsvchiatrv 1992; 25:126-135.
22. Lienert GA: Testaufbau und Testanalvsc, ed 2 Test Construction and Test Analysis, Wein-heim, Beltz, 1967.
23. Weyer G, Erzigkeit H, Hadler D, Kubicki S: Efficacy and safety of idebcnone in the longterm treatment of Alzheimer's disease: A double-blind, placebo-controlled multiccntre study, Human Psychopharmacol 1996:11:53-65.
24. Pantev M, Ritter R, Gortclmcyer R: Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under mcmantine treatment, Z Gerontopsycholge-rontopsychiatrie 1993:6:103-117.
25. Barlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, for the Tacrine Study Group: A controlled trial of tacrine in Alzheimer's disease, JAMA 1992:268:2523-2529.
26. Knapp MJ, Gracon SI, Davis CS, Solomon PR, Pendleburv WW, Knopman DS: Efficacy and safety of high-dose tacrine: A 30-week evaluation, Alzheimer Dis Rclat Disord 1994; 8(suppl 2):S22-S31.